Gilead (GILD) Q1 'One of Most Impressive Beats in Biopharma History' - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gilead Sciences (GILD) Q1 Results Called 'Outstanding' at Wells Fargo
April 23, 2014 9:36 AM EDTWells Fargo maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $87-$91. Analyst Brian Abrahams described Q1 results as "outstanding."
"On 4/22, GILD reported outstanding quarterly results, with Sovaldi sales likely exceeding most sell/buyside expectations, some... More
Goldman Sachs Comments on Gilead Sciences (GILD) Q1
April 23, 2014 7:46 AM EDTGoldman Sachs maintained a Neutral rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $65.00 (from $63.00).
Analyst Terence Flynn said, "Sovaldi posted an impressive beat in its first full quarter on the US market... More
Gilead Sciences (GILD) Q1 'As Good as it Gets' - Nomura
April 23, 2014 7:39 AM EDTNomura Securities analyst M. Ian Somaiya reiterated a Buy rating and boosted his price target on Gilead Sciences (NASDAQ: GILD) from $121 to $130 calling Q1 'as good as it gets.'
We are raising our HCV sales estimates and target price to $130 from $121 following... More
Gilead Sciences, Inc. (GILD) Tops Q1 EPS by 61c, Offers Guidance
April 22, 2014 4:30 PM EDTGilead Sciences, Inc. (NASDAQ: GILD) reported Q1 EPS of $1.46, $0.61 better than the analyst estimate of $0.85. Revenue for the quarter came in at $5 billion versus the consensus estimate of $3.8 billion.
Full Year 2014 Guidance
Gilead reiterates its full year 2014 guidance, initially provided on February 4, 2014,... More
